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ABSTRACT Antibiotic intervention is an effective treatment strategy for many bacterial infections and liberates bacterial
antigens and stimulatory products that can induce an inflammatory response. Despite the opportunity for bacterial killing
to enhance the development of adaptive immunity, patients treated successfully with antibiotics can suffer from reinfec-
tion. Studies in mouse models of Salmonella and Chlamydia infection also demonstrate that early antibiotic intervention
reduces host protective immunity to subsequent infection. This heightened susceptibility to reinfection correlates with
poor development of Th1 and antibody responses in antibiotic-treated mice but can be overcome by delayed antibiotic in-
tervention, thus suggesting a requirement for sustained T cell stimulation for protection. Although the contribution of
memory T cell subsets is imperfectly understood in both of these infection models, a protective role for noncirculating
memory cells is suggested by recent studies. Together, these data propose a model where antibiotic treatment specifically
interrupts tissue-resident memory T cell formation. Greater understanding of the mechanistic basis of this phenomenon
might suggest therapeutic interventions to restore a protective memory response in antibiotic-treated patients, thus reduc-
ing the incidence of reinfection.
Since the discovery of penicillin in 1928, antibiotics have beenwidely used to treat bacterial infections, and as a result, bacte-
ria have rapidly developed antibiotic resistance (1, 2). The devel-
opment of multidrug-resistant (MDR) bacteria is now a critical
issue in modern medicine, with the concern that serious bacterial
infections will reemerge in the 21st century in the absence of ef-
fective treatment options (3–6). Despite this important issue, an-
tibiotics remain an effective treatment option for many common
infectious diseases.
An adaptive immune response to infection is initiated by rec-
ognition of foreign protein antigens in the presence of local in-
flammation (7). The contextual inflammatory cues come from
innate immune cells that encounter bacterial products, and these
signals profoundly affect the subsequent adaptive immune re-
sponse (8). This initial activation stage occurs within local lymph
nodes and causes low-frequency naive T cells and B cells to pro-
duce an army of effector cells to eradicate a complex pathogen (9,
10). Effective antibiotic therapy will kill a large number of bacte-
ria, thus liberating antigen for lymphocyte recognition and releas-
ing bacterial products that can amplify local inflammatory re-
sponses. Thus, antibiotics have a direct effect on bacterial growth
but also have the potential to enhance an ongoing pathogen-
specific adaptive immune response. However, many studies have
shown that antibiotic administration can paradoxically weaken
immune memory, leaving a recovered host fully susceptible to
reinfection with the same pathogen (11–13). The mechanistic ba-
sis for this detrimental effect of antibiotics on immune memory
and protection is incompletely understood. A more detailed un-
derstanding of this phenomenon might allow the development of
targeted strategies to encourage immune memory development
and support long-lasting protection from reinfection. In this re-
view, we will discuss this issue in the context of recent findings
from mouse models of Salmonella and Chlamydia infection, since
both models show a detrimental effect of antibiotics upon the
development of immune memory.
HUMAN SALMONELLA AND CHLAMYDIA INFECTIONS
Salmonella bacteria cause a variety of clinical diseases, depending
on the bacterial serovar and the underlying susceptibility of the
infected host (14, 15). In many low-income countries with limited
infrastructure, Salmonella enterica serovars Typhi and Paratyphi
are transferred via the fecal-oral route and can cause enteric fever
(16). While enteric fever can be successfully treated using antibi-
otics, the prevalence of multidrug-resistant strains is increasingly
an impediment to treatment in areas where it is endemic (13). The
administration of ciprofloxacin (a fluoroquine derivative) for 7 to
14 days is often sufficient to ensure the recovery of infected pa-
tients, but this depends upon the local prevalence of MDR strains
(13, 17). Interestingly, even when treatment is successful, a cohort
of patients suffer relapsing disease or can be reinfected with dif-
ferent Salmonella Typhi or Paratyphi strains at a later date. Thus,
the successful resolution of primary infection with antibiotics
does not guarantee the acquisition of protective immunity to re-
infection.
Salmonella are not the only intracellular bacteria for which a
lack of secondary protection is observed following antibiotic treat-
ment. Chlamydia trachomatis is an obligate intracellular bacte-
rium that causes ocular and sexually transmitted infections world-
wide (18). In the United States, Chlamydia causes over 1.4 million
sexually transmitted infections annually, and the health care costs
associated with these infections amount to $500 million every year
(19, 20). Immunity to Chlamydia infection in asymptomatic
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women develops slowly, and 50% of women continue to shed
bacteria for a year (21). Since persistent or recurrent infection is a
major risk factor for pelvic inflammatory disease (22, 23), Chla-
mydia control programs were introduced to reduce the burden of
disease. These “seek and treat” programs have not reduced the
incidence of Chlamydia infection but have reduced the incidence
of associated pathology (24–27). However, reinfection is often
observed following successful antibiotic treatment (24, 28), indi-
cating that protective memory responses fail to develop in
antibiotic-treated patients. Indeed, it has been argued that antibi-
otic treatment is counterproductive to the generation of Chla-
mydia immunity, an idea that is often referred to as the “arrested
immunity” hypothesis (12). Recent clinical data support this hy-
pothesis, since women who spontaneously resolve Chlamydia
infection have a lower incidence of reinfection than antibiotic-
treated women (29). Furthermore, gamma interferon (IFN-)-
producingChlamydia-specific Th1 cells develop slowly and do not
persist in the circulation of women after effective antibiotic treat-
ment (30). Thus, the high reinfection rates found in large popu-
lation studies could actually be a consequence of early interven-
tion programs that seek to screen and treat Chlamydia-infected
women (24, 31). Together, these studies suggest findings that par-
allel those from Salmonella-infected patients and indicate that
protective immunity does not develop effectively following anti-
biotic treatment of Chlamydia.
PROTECTIVE IMMUNITY TO INTRACELLULAR BACTERIA
Since antibiotic treatment appears to have a negative impact on
host protective immunity to secondary bacterial infection, it is
vitally important to determine the mechanism of this phenome-
non. The basic cellular immune responses to Salmonella andChla-
mydia infection have been elucidated in mouse models and share
common features (32–34). As expected for intracellular bacteria,
CD4 Th1 cells that express T-bet and produce IFN- are critical
for bacterial clearance. Thus, mice lacking major histocompatibil-
ity complex (MHC) class II-restricted T cells, T-bet, or IFN-
succumb to primary infection with attenuated S. enterica serovar
Typhimurium, an infection that resolves naturally in wild-type
mice (35, 36). In contrast, mice lacking MHC class I-restricted
CD8 T cells or B cells display only minor deficiencies in clearing
primary Salmonella infection (37–39). Similarly, mice lacking
MHC class II-restricted CD4 T cells or IFN- have difficulty re-
solving primary Chlamydia infection (40, 41), and yet, CD8 T cells
or B cells are not essential (40, 42, 43). Together, these data point
to a major role for CD4 Th1 cells in primary clearance of both
Salmonella and Chlamydia infections. However, despite the fact
that Salmonella and Chlamydia replicate intracellularly, antibody
responses can play an important additive role during secondary
infection (38, 39, 44, 45). Thus, memory CD4 T cells and circulat-
ing antibody can both be involved in effective clearance of bacteria
during secondary infection (32, 33).
Persisting memory T cells contain at least three distinct sub-
sets, each displaying different functional capabilities and tissue-
homing potential (46, 47). Central memory T cells (TCM) recir-
culate between the blood and lymph fluid and have low immediate
effector potential, similar to naive T cells. In contrast, effector
memory T cells (TEM) display high immediate effector potential
and can recirculate between blood and nonlymphoid tissues, an-
atomical locations where they are likely to encounter secondary
bacterial infection. Finally, a population of resident memory T
cells (TRM) remains within nonlymphoid tissues and has high
immediate effector potential. This heterogeneity in T cell memory
is important, since some infections show a greater reliance on
tissue-resident versus circulating memory cells for pathogen
clearance (48). While the protective contribution of distinct T cell
memory subsets has not been fully explored in Salmonella infec-
tion models, recent data demonstrate that TRM CD4 T cells are
critically important for immunity to Chlamydia infection (49).
Thus, deficiency in secondary protective immunity to Salmonella
and Chlamydia infection seems likely to involve CD4 T cell mem-
ory and may reflect an alteration in generating a specific protective
subset.
ANTIBIOTIC CLEARANCE OF SALMONELLA IN THE MOUSE
MODEL
Two different mouse models are commonly used to investigate
the immune response to Salmonella infection (50). The first model
involves infecting genetically resistant mice with virulent Salmo-
nella Typhimurium, thus allowing detailed study of innate and
adaptive immune responses during the natural resolution of Sal-
monella infection (51). The alternative approach is to infect genet-
ically susceptible mice with attenuated Salmonella strains, again
allowing basic analysis of immune responses to primary bacterial
infection (10). The obvious caveat to this second model is that the
bacteria used are not fully virulent; however, the basic mechanism
of primary clearance appears similar in both models. As noted
above, protective immunity to secondary infection requires the
cooperation of CD4 T cells and Salmonella-specific antibody re-
sponses. Importantly, in the genetically resistant model, protec-
tive immunity to reinfection can be transferred by antibody alone
(52, 53), making this model less useful for examining CD4 T cell
memory. Since humans require MHC class II-restricted T cell re-
sponses for efficient resolution of Salmonella infection (54), the
susceptible mouse model is often used when studying the protec-
tive role of CD4 T cells against secondary infection.
Since many human typhoid infections are resolved by antibi-
otic treatment, our laboratory previously developed a mouse
model in which susceptible mice were challenged with highly vir-
ulent Salmonella bacteria and antibiotics used to resolve primary
infection. This proved more difficult than expected, and a full
5 weeks of enrofloxacin administration was required for C57BL/6
mice to completely resolve a primary infection with Salmonella
Typhimurium (55). Live imaging experiments demonstrated that
while viable bacteria were cleared from the spleen, liver, and bone
marrow within 72 h of antibiotic treatment, a small population of
bacteria persisted in mesenteric lymph node (MLN) phagocytes
for several weeks after treatment (56). Thus, the removal of anti-
biotics before this population was eradicated allowed the out-
growth of bacteria and resumption of clinical disease. Indeed, re-
lapse of primary infection was previously observed after treatment
of murine infection with ampicillin and is also common to human
salmonellosis (16, 57). Importantly, this relapsing disease does not
require the development of antibiotic resistance, and these late-
outgrowth bacteria remain susceptible to antibiotics (55). Simi-
larly, in the resistant mouse model, recovery from primary infec-
tion is associated with continued bacterial shedding, indicating a
chronic infection (58). Although persisting infection in both
models is often localized to the MLNs (56, 58), surgical removal of
the MLNs actually increased relapsing disease in antibiotic-
treated mice (56), suggesting that the true site of bacterial persis-
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tence is more likely to be upstream from MLN afferent lymph
drainage. Salmonella persistence has been correlated with the abil-
ity of some bacteria to enter a dormant state in which they are
largely refractory to the effect of antibiotics (59, 60). However,
recent studies have shown that outgrowing bacteria actually derive
from bacteria with an intermediate growth phenotype that remain
partially sensitive to antibiotic treatment (61). Thus, Salmonella
bacteria display the ability to persist in the face of antibiotic treat-
ment and in mice genetically predisposed to resolve primary in-
fection. Given the wide availability of bacterial antigens for recog-
nition by the host innate and adaptive immune system in these
models, it is perplexing that relapsing infection can still occur
many weeks after primary infection. The inability of the host im-
mune system to effectively clear persistent or relapsing Salmonella
infection might be due to effective immune evasion strategies em-
ployed by the bacteria (62–64).
Susceptible mice treated for at least 5 weeks with enrofloxacin
were able to fully resolve primary Salmonella infection, and these
mice did not suffer from relapsing disease (55). This model therefore
allowed a comparison of secondary protective immunity following
antibiotic resolution of infection and naturally resolved primary in-
fection with attenuated bacteria. While mice administered attenuated
bacteria generated robust protective immunity to secondary infec-
tion, antibiotic-treated mice remained susceptible to Salmonella in-
fection, although they survived longer than naive mice (55). These
data point to an underlying deficiency in the acquisition of protective
memory following antibiotic treatment that is similar to the suscep-
tibility to reinfection observed in human disease (16). The weak pro-
tective immunity that was evident in antibiotic-treated mice required
MHC class II-restricted T cells, B cells, and IFN- (55). When adap-
tive immune responses were examined in antibiotic-treated mice, it
was noted that antibody responses were slightly depressed and the
frequency of IFN--producing cells was significantly reduced (55,
56). In recent experiments using MHC class II tetramers to track
endogenous CD4 T cell responses to Salmonella, our laboratory has
found that antibiotic treatment reduces the overall size of the
Salmonella-specific CD4 memory pool (J. M. Benoun and S. J. Mc-
Sorley, unpublished data). Thus, appropriate protective mechanisms
appear to be engaged in antibiotic-treated mice, but the overall re-
sponse is reduced, preventing a robust response to secondary infec-
tion (Fig. 1).
Previous studies have shown that CD4 clonal expansion and
memory formation require sustained antigen presentation over sev-
eral days (65, 66). Although antibiotic treatment liberates antigens
from dead bacteria, it seems likely that this period of antigen presen-
tation could be short, thus adversely impacting CD4 memory. In-
deed, when antigen presentation is prolonged by delaying antibiotic
intervention, this allows robust protective responses to emerge (56).
This increased protection also coincides with a gradual increase in
Salmonella-specific Th1 responses (56), suggesting that a prolonged
period of antigen stimulation allows the recovery of memory devel-
opment. Indeed, full recovery of Th1 responses required 14 days of
exposure to live bacteria prior to antibiotic intervention (56). Thus, a
major factor driving the detrimental impact of antibiotics upon pro-
tective memory responses is rapid elimination of bacterial antigens
before memory CD4 T cells fully develop. Since CD8 T cells are
thought to be less dependent on sustained antigen presentation (65–
68), infections that rely on CD8 T cells for pathogen clearance might
show less of a detrimental effect of antibiotics upon memory devel-
opment. However, although initial CD8 responses occur normally
with only a short period of antigen presentation, CD8 memory re-
sponses are still dependent to some extent upon prolonged antigen
stimulation (69). In addition to sustained antigen stimulation, CD4 T
cells also require costimulatory signals and local cytokines to develop
appropriate functional responses (7). The availability of these co-
stimulatory signals and cytokines is also likely to diminish as antibi-
FIG 1 Antibiotic treatment reduces the development of T cell memory. Primary bacterial infection initiates the expansion of T cells that aid in clearance of the bacteria,
leaving a pool of memory T cells behind. Upon secondary infection, these memory cells have acquired effector potential and can eliminate bacteria rapidly. Antibiotic
treatment of primary infection truncates T cell expansion and limits memory cell development, preventing an effective response to secondary infection.
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otics rapidly resolve a primary bacterial infection. It will therefore be
important to define precisely which of these signals is lacking in
antibiotic-treated mice, since it may be possible to deliver these sig-
nals therapeutically during the period of antibiotic treatment.
ANTIBIOTIC CLEARANCE OF CHLAMYDIA IN THE MOUSE
MODEL
Investigators studying immunity toChlamydiamake use of two com-
plementary mouse models (32, 70). In the first model, investigators
useChlamydia trachomatis to infect in-bred mouse strains, which has
the obvious advantage of using the human pathogen directly in these
model studies. However, Chlamydia trachomatis is not a natural
pathogen of mice, and many laboratories therefore choose to exam-
ine immunity to Chlamydia muridarum, which causes an ascending
reproductive tract infection following vaginal inoculation. Chla-
mydia bacteria have the ability to fuse and form noninfectious aber-
rant bodies under antibiotic pressure, and this form of the pathogen is
known to be refractory to antibiotic killing (71, 72). There is also
evidence that Chlamydia can persist in the intestine during an im-
mune response or antibiotic treatment that can effectively clear bac-
teria from the reproductive tract (73, 74). Thus, Chlamydia and Sal-
monella each have the ability to persist in the face of antibiotic
treatment, and for both these organisms, this may involve low-level
chronic infection of intestinal tissues.
Secondary protective immunity has been examined following
antibiotic clearance of Chlamydia infection in the mouse model.
As with the Salmonella mouse model, successful treatment of
Chlamydia infection in mice reduced protective immunity to sub-
sequent secondary challenge compared to the protective immu-
nity in mice that resolved primary infection naturally (75). Similar
to Salmonella infection, the mechanistic basis of this arrested im-
munity is largely unknown but can be mitigated by delaying the
start of antibiotic treatment (75), presumably because this allows
more time for CD4 T cell memory to develop. Interestingly, ad-
ministering a suboptimal dose of antibiotic creates a self-limiting
subclinical infection, and these mice develop stronger adaptive
responses and robust protective immunity as a result (76). The
detrimental effect of antibiotic intervention in the Chlamydia
model also correlates with lower Chlamydia-specific antibody re-
sponses and a reduced ability of splenocytes to produce IFN- in
response to Chlamydia antigens (75). Thus, similar to the Salmo-
nella model, rapid bacterial clearance using antibiotics is associ-
ated with the development of a dysfunctional memory response.
While CD4 T cells are essential for immunity to genital C. mu-
ridarum infection, the specific contribution of each TCM, TEM,
and TRM subset has yet to be firmly established. Importantly,
noncirculating tissue-resident memory (TRM) T cells have been
identified as an essential component of protection at mucosal sur-
faces (77). Cells of this population typically have rapid effector
capability, adopt tissue-specific differentiation patterns, and can
initiate rapid innate immune responses to secondary infection
(77–79). However, given the tissue-restricted localization of TRM
T cells and the difficulty quantifying this population by flow cy-
tometry, a comparative analysis of these subsets in the Chlamydia
model is not trivial to complete (80). Recent studies have shown
that repeated use of antibiotics to control a primary Chlamydia
infection induces effector memory CD4 T cells in local draining
lymph nodes (81), but the relationship between this population
and effective protective immunity has not been established. As
noted above, data from parabiosis experiments have shown that
nonrecirculating memory cells are critical for protective immu-
nity using a prototype Chlamydia vaccine (49). Thus, noncircu-
lating TRM T cells would seem to be an integral component of
protective immunity to secondary infection with Chlamydia (34).
Therefore, it seems likely that antibiotic treatment during
Chlamydia infection will adversely affect the development of
Chlamydia-specific TRM within the reproductive tract, but this
issue has yet to be examined experimentally.
CONCLUSION
A number of experiments from Salmonella and Chlamydia infec-
tion models suggest that early antibiotic intervention impedes the
development of effective protective memory, which is largely me-
diated by Th1 CD4 cells. The duration of antigen presentation and
inflammatory stimulation are known to be key variables in the
generation of CD4 T cell memory, and both of these variables are
likely to be adversely affected by antibiotic administration. It is not
yet clear whether this deficiency in CD4 T cell responses could be
overcome by administering additional antigen or adjuvants dur-
ing the period of antibiotic administration. Using the Salmonella
infection model, we administered purified bacterial flagellin to
mice being treated with antibiotic and detected the recovery of
robust protective immunity to secondary infection (55). This ex-
periment suggests that it may be possible to support the develop-
ment of an effective memory lymphocyte population during an-
tibiotic administration and that this can ultimately be of
considerable benefit to the host. However, given the role of bacte-
rial flagellin as a CD4 T cell target antigen and an inducer of in-
flammatory responses (82, 83), it still remains unclear whether
providing antigen or adjuvant is the most effective strategy to
recover protective memory responses. Future experiments will fo-
cus on whether the immune responses that are boosted in this
context come from circulating or noncirculating memory cells.
Greater understanding of the mechanisms of impaired adaptive
immune responses after antibiotic treatment may allow simple
and effective therapeutic strategies that could be easily translated
to protect against repeated bacterial infections.
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